ArticleJournal of clinical medicine2023

Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors.

Francesca Guidetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.